Corporate Presentation

ZEAL& ZEALAND PHARMA Significant events and potential catalysts in 2024 NON-EXHAUSTIVE H1 2024 Petrelintide Topline results from 16-week Phase 1b MAD trial Dapiglutide Topline results from Phase 2a investigator-initiated trial DREAM Survodutide¹ Present results from Phase 2 MASH trial at scientific congress Dasiglucagon (CHI) NDA resubmission to US FDA for three weeks of dosing Dasiglucagon (CHI) Submission to US FDA of analyses supporting chronic use Legend: Obesity Rare diseases Inflammation H2 2024 Petrelintide Initiate Phase 2b trial Dapiglutide Topline results from 13-week Phase 1b dose-titration trial Survodutide¹ Enroll Phase 3 SYNCHRONIZE program² Dasiglucagon (CHI) Potential US regulatory approval Glepaglutide (SBS) Potential US regulatory approval ZP9830 (Kv1.3 Ion Channel Blocker) Initiation of first-in-human clinical trials ZP100683 (complement C3 inhibitor) Initiation of first-in-human clinical trials Potential partnership agreements across therapeutics areas Notes: 1) Survodutide is licensed to Boehringer Ingelheim from Zealand Pharma, with Boehringer solely responsible for development and commercialization globally (subject to Zealand's co-promotion rights in the Nordic countries). 2) SYNCHRONIZETM-1 and SYNCHRONIZE™M-2. 3) Licensed to Alexion, responsible for all clinical development. 51

View entire presentation